Baseline characteristics and current state of patients
| # | Gender | Age (years) | Failed DSZ w/o OMZ | Casein sIgE | α-LA sIgE | β-LG sIgE | OVM sIgE | OVA sIgE | Courses of OMZ | Current OMZ | Current tolerance |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 8 | No | 15 | 7 | 0 | - | - | 1 | Yes | No |
| 2 | F | 4.3 | Yes | 34 | 9 | 10 | - | - | 1 | Yes | No |
| 3 | M | 5.4 | No | 2,040 | 84 | 294 | - | - | 1 | Yes | Yes |
| 4 | F | 3.7 | Yes | 1 | 7 | 2 | - | - | 1 | No | Yes |
| 5 | M | 16.6 | No | 58 | 11 | 18 | - | - | 1 | No | Yes |
| 6 | F | 3.7 | Yes | 64 | 21 | 9 | - | - | 1 | No | Yes |
| 7 | M | 4.1 | No | 128 | 34 | 14 | - | - | 1 | No | Yes |
| 8 | F | 4.1 | Yes | 308 | 43 | 12 | - | - | 1 | No | Yes |
| 9 | M | 6 | No | 869 | 41 | 12 | - | - | 1 | No | Yes |
| 10 | M | 7.5 | Yes | - | - | - | 4 | 2 | 1 | No | Yes |
| 11 | M | 6.2 | Yes | - | - | - | > 100 | 78 | 1 | No | Yes |
| 12 | F | 8.6 | Yes | - | - | - | 3 | 1 | 1 | No | No |
| 13 | F | 4 | Yes | 75 | 28 | 28 | - | - | 2 | No | Yes |
| 14 | M | 3.5 | Yes | 833 | - | - | - | - | 2 | No | Yes |
| 15 | F | 10.7 | No | - | - | - | 340 | 690 | 2 | No | Yes |
| 16 | M | 10.6 | No | - | - | - | 95 | 335 | 2 | No | Yes |
| 17 | F | 10.1 | Yes | - | - | - | 135 | 155 | 2 | No | Yes |
| 18 | M | 6.3 | No | - | - | - | 48 | 9 | 2 | No | Yes |
| 19 | F | 8.8 | Yes | - | - | - | > 100 | 14 | 2 | No | No |
| 20 | F | 10.8 | Yes | - | - | - | 18 | 32 | 2 | No | No |
| 21 | M | 6.7 | Yes | - | - | - | 30 | 32 | 2 | No | No |
sIgE in kUA/L. M: male; F: female; w/o: without; α-LA: α-lactalbumin; β-LG: β-lactoglobulin; OVA: ovalbumin. -: not applicable. Diluted serum was used, when enough sample was available, to measure sIgE > 100 kUA/L